Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT06816017 2025-06-16

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06663137 2025-06-13

HGNMIBC

Phase 2 Recruiting

70 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06678633 2025-05-29

T-Control® Safety for Cytostatics Management

Phase NA Not yet recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06800963 2025-05-16

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Not yet recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05945108 2025-04-11

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Completed

400 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05981131 2025-03-13

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active not recruiting

6 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05085977 2025-01-27

ADVANCED-1

Phase 1 Completed

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05085990 2025-01-27

ADVANCED-1

Phase 1 Completed

10 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06186414 2025-01-15

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Phase 1 Recruiting

152 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06448364 2024-11-06

LTbR

Phase 1 Terminated

4 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

SURF302

ADVANCED-3

SunRISe-5

BOND-003

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

MoonRISe-1

MoonRISe-3

Nova-sTAR

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

RESCUE

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

TroFuse-027

ABLE-41

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

ADVANCED-2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

CREST

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

UTOPIA

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

SURF301

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

ENAiBLE

BLCCR

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

POTOMAC

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

HIVEC

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

PARADIGM-1

TIM

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

HGNMIBC

T-Control® Safety for Cytostatics Management

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

ADVANCED-1

ADVANCED-1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

LTbR